The global Hepatitis C Treatment Market size was estimated at USD 52.63 Bn in 2021, growing at a CAGR of12.6% during the forecast period 2021-2027. Hepatitis C is an infectious disease caused by the Hepatitis C virus (HCV) and affects primarily the liver. Hepatitis C is commonly caused by blood to blood contacts such as intravenous drug use, unsterilized equipment, blood transfusions, and sexual intercourse. Hepatitis C may also cause from mother to fetus during birth. People with alcoholism and HIV infection of any age group are at increased risk. Currently, there is no vaccine available to treat hepatitis C conditions. However, various drugs such as protease inhibitors, HCV polymerase inhibitors, and HCV NS5A inhibitors are commonly used to treat Hepatitis C. Early stage of infection typically has no symptoms. The critical stage of infection may display symptoms such as fever, dark urine, abdominal pain, and yellow-tinged skin occurrence. The severity in hepatitis C may lead to liver cirrhosis, liver cancer, liver failure, and sometimes also causes the dilated blood vessels in the esophagus and stomach. Hepatitis C can be prevented by using sterilized equipment, screening of blood donors, avoiding multiple sexual partners, and avoiding sharing of injections and razors. According to the World Health Organization (WHO), globally there are 80 Mn people suffer from chronic hepatitis C virus, in that approximately 700,000 will die each year as a result of the infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their market share in global hepatitis C treatment market. For instance, in July 2011, Merck MSD inked an agreement with Roche for the marketing approvals of Victreli (Boceprevir) triple combination therapy with peginterferon alfa and ribavirin (peg/riba). In addition, in August 2011, Vertex Pharmaceuticals Incorporated announced that Health Canada approved its Incivektm (Telaprevir) tablets for people with genotype 1 chronic hepatitis C with compensated liver disease. In January 2014, European Commission (EC) granted marketing authorization for Gilead’s Sovaldi (Sofosbuvir) to treat chronic hepatitis C infection.